Sage Journals: Discover world-class research

Abstract

With the completion of several phase 2 and phase 3 clinical studies, the efficacy and tolerability of alefacept in patients with chronic plaque psoriasis is now well studied. The majority of patients treated with a single course of intravenous or intramuscular alefacept experienced a clinically meaningful response. The efficacy of alefacept correlated with its ability to selectively target and reduce the number of pathogenic memory T cells. A second course of alefacept resulted in further clinical improvement, with increasing response rates and prolonged response duration following treatment cessation. Sub-population analyses demonstrated that alefacept is effective in a broad spectrum of patients with psoriasis, regardless of disease severity, history of and response to prior antipsoriatic treatment, or whether patients are refractory to or have contraindications to other systemic psoriasis therapies or phototherapy.

Get full access to this article

View all access options for this article.

References

Krueger

Koo

Lebwohl

. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280–284.

Prinz

. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17:257–270.

Gottlieb

Bos

. Recombinantly engineered human proteins: Transforming the treatment of psoriasis. Clin Immunol 2002; 105:105–116.

Ellis

Krueger

, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345:248–255.

Krueger

Papp

Stough

, for the Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47:821–833.

Lebwohl

Christophers

Langley

, for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139:719–727.

Gordon

Langley

. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003; 2:624–628.

Fredriksson

Pettersson

. Severe psoriasis—oral therapy with a new retinoid. Dermatologica 1978; 157:238–244.

Carlin

Feldman

Krueger

. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50:859–866.

10.

Gordon

Vaishnaw

O'Gorman

, for the Alefacept Clinical Study Group. Treatment of psoriasis with alefacept. Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003; 139:1563–1570.

11.

Ortonne

J-P

Lebwohl

Griffiths

CEM

. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003; 13:117–123.

12.

Vaishnaw

Ticho

. Alefacept is efficacious in a broad spectrum of patients with psoriasis, including those with severe disease. Poster presented at the 61st Annual Meeting of the American Academy of Dermatology, 21–26 March 2003, San Francisco, CA.

13.

van de Kerkhof

Vaishnaw

Kragballe

. Alefacept is efficacious in a broad spectrum of patients with psoriasis [abstract]. J Eur Acad Dermatol Venereol 2003; 17(Suppl 1):55.

14.

Christophers

O'Gorman

Vaishnaw

. Pooled efficacy of alefacept in psoriasis patients who were refractory to or who had contraindications to other systemic psoriasis treatments or phototherapies. Poster presented at the 9th International Psoriasis Symposium, 18–22 June 2003, New York.

15.

Ortonne

J-P

Khemis

. Combination therapy with alefacept plus narrowband ultraviolet B light for treatment of psoriasis. Poster presented at the 9th International Psoriasis Symposium, 18–22 June 2003, New York.

16.

Koo

. Combination therapy with alefacept plus broadband ultraviolet B light for treatment of psoriasis. Poster presented at the 9th International Psoriasis Symposium, 18–22 June 2003, New York.

17.

Krueger

Gordon

van de Kerkhof

. Repeated courses of IM alefacept in psoriasis: Rationale and design of an international study that mimics the clinical practice setting. Poster presented at the International Investigative Dermatology Meeting, 30 April–4 May 2003, Miami Beach, FL.

The Efficacy of Alefacept in the Treatment of Chronic Plaque Psoriasis

Abstract

Get full access to this article

References